4-hydroxyandrostenedione
4-hydroxyandrostenedione (4-OHA), the       first selective aromatase inhibitor, has been shown to reduce serum estrogen       concentrations and cause complete and partial responses in approximately 25% of       patients with hormone responsive disease who have relapsed from previous       endocrine treatment.
 @SUBJECT$  @PREDICAT$  @OBJECT$ , has been shown to reduce serum estrogen       concentrations and cause complete and partial responses in approximately 25% of       patients with hormone responsive disease who have relapsed from previous       endocrine treatment.